意大利贵宾会  宣布时间:2016-06-27 15:51:22 作者:SystemMaster
FiercePharma 2018-6-21文章(全文翻译)

When Takeda’s gout drug Uloric (febuxostat) was approved by the FDA, it was with a requirement for postmarketing studies to further assess its safety. Now a nonprofit consumer advocacy group says the FDA should remove the drug from the U.S. market after findings released this March show significant deadly heart risks.


In a petition (PDF) sent to the FDA on Thursday, Public Citizen stated there is “overwhelming evidence that the serious cardiovascular harms of [Uloric] outweigh any purported clinical benefit,” and that leaving it on the market would only cause “further preventable harm” to patients.


The Japanese pharma submitted results from a postmarketing cardiovascular safety study previously required by the FDA in January, and it is “working with the agency to conduct a comprehensive review of this data,” a Takeda spokeswoman told FiercePharma.


A spokesman for the FDA told FiercePharma the agency will review Public Citizen’s letter and will respond directly to the organization.


The 2009 approval allowed Uloric to be used as a treatment of hyperuricemia—instead of for the direct reduction in gout flares—in gout patients. But it followed two failed attempts in 2005 and 2006 under TAP Pharmaceutical.


The FDA had rejected the medication out of concerns for increased cardiovascular risks observed in clinical trials. At the time of the second NDA submission, FDA reviewers noted 9 of the total 12 deaths among subjects on Uloric were attributable to CV causes, whereas no serious adverse CV events were linked to comparator allopurinol or placebo.


In response to the FDA’s concern, Takeda conducted another trial that ultimately didn’t find the same CV safety signal. But after putting data from all three phase 3 studies and two long-term extension studies together, the FDA reviewers couldn’t determine “with much confidence” whether Uloric poses greater risk. So, when they did approve the drug, they slapped a warning on the drug’s label and asked Takeda to run a large, postmakreting study to further examine Uloric’s CV safety profile.


Concerns flared up on Nov. 15, 2017, when the FDA issued a drug safety communication alerting the public of increased cardiovascular events with Uloric, compared to allopurinol. The agency at that time said it will “conduct a comprehensive review and will update the public with any new information,” once it has the full final result


Findings from the 6,190-subject study were then published this March in The New England Journal of Medicine. In that study, researchers noted that after 32 months, overall adverse CV events were similar in both arms, but “[a]ll-cause mortality and cardiovascular mortality were higher with [Uloric] than with allopurinol.”

今年3月新英格兰医学杂志宣布该项6,190例痛风患者的研究结果。指出在该研究中,研究人员发明平均治疗32个月后,非布司他和别嘌醇治疗组总体的不良心血管事件相似,可是非布司他组的全因死亡率和心血管死亡率高于别嘌呤醇组(注:非布司他组患者心血管死亡危害增加34%(HR 1.34,95% CI,1.03-1.73),全因死亡率增加22%(HR 1.22,95% CI,1.01-1.47)。其中,心脏性猝死最常见-非布司他组83例(2.7%),别嘌醇组56例(1.8%))。

Following the release of the study, Takeda said in a statement that the reason for the imbalance in cardiovascular deaths has not been identified.


“The agency should have demanded that an appropriately designed clinical trial to assess febuxostat’s cardiovascular risks be conducted before, not after approval,” said Michael Carome, M.D., director of Public Citizen’s Health Research Group, in a statement. “The FDA almost certainly would have denied approval of febuxostat if data from this post-market trial had been available at the time of the initial submission.”

公共公民健康研究机构卖力人医学博士Michael Carome指出,FDA应该要求在批准非布司他上市前而不是上市后设计适当的临床试验以评估非布司他的心血管危害。在该机构一项申明中提出,如果这个上市后临床研究数据在最初提交相关资料时就提供,险些可以肯定FDA会拒绝批准非布司他上市!

Besides higher risks of cardiovascular risks, the organization also argued there’s not enough data showing Uloric is more effective in the actual prevention of gout flares, other than that it’s able to lower serum uric acid levels, which can cause acute painful gout episodes.